RISK ASSESSMENT - PRESENT AND FUTURE

被引:0
|
作者
WADA, O
KURIHARA, N
GAO, Q
机构
关键词
RISK ASSESSMENT; RISK MANAGEMENT; RISK COMMUNICATION; PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL (PBPK); BIOLOGICALLY-BASED PHARMACODYNAMIC MODEL (BBPB);
D O I
暂无
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Risk assessment is a scientific endeavour to evaluate and estimate the exposure to a sub stance and its consequent adverse health effects by the use of the available scientific information. The four phases of the risk assessment include hazard identification, exposure estimation, dose-response assessment and risk characterization. Recently, risk management and risk communication have been added as its final components. Bt present, however, methods for identifying toxicants and exposed individuals and populations, models for inferring human health effects from animal studies, techniques for estimating risks and predicting health effects with few data are all in need of improvement or development. Fortunately, remarkable advances in biotoxicology and molecular biology have promoted new understandings in the mechanism of disease. Incorporation of these new data moved the evaluation closer to the goal of estimating actual human risks. Recently developed physiologically-based pharmacokinetic models far the estimation of active chemical levels at critical organs and their conjugation with biologically-based pharmacodynamic models of the process of carcinogenesis seem to be not only an essential part of a rational approach to quantitative cancer risk assessment, but also raise fundamental questions about the nature of the events leading to malignancy. These scientific progress will develop sound risk assessment, dissolve the wide divergency in regulatory decisions of agencies in different countries, and lead to better health protection.
引用
收藏
页码:256 / 273
页数:18
相关论文
共 50 条
  • [1] Present and future of coronary risk assessment
    Prati, Francesco
    Biccire, Flavio Giuseppe
    Budassi, Simone
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0E) : E123 - E127
  • [2] The Present and Future of Lipid Testing in Cardiovascular Risk Assessment
    White-Al Habeeb, Nicole M. A.
    Higgins, Victoria
    Wolska, Anna
    Delaney, Sarah R.
    Remaley, Alan T.
    Beriault, Daniel R.
    [J]. CLINICAL CHEMISTRY, 2023, 69 (05) : 456 - 469
  • [3] Immunotoxicology and risk assessment - Present prospects, future directions
    Chapman, PM
    [J]. HUMAN AND ECOLOGICAL RISK ASSESSMENT, 2002, 8 (02): : 251 - 252
  • [4] Use of mode of action in risk assessment: Past, present, and future
    Clewell, H
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2005, 42 (01) : 3 - 14
  • [5] Food safety risk assessment in China: Past, present and future
    Wu, Yong-ning
    Liu, Pei
    Chen, Jun-shi
    [J]. FOOD CONTROL, 2018, 90 : 212 - 221
  • [6] The challenge: Pollinator risk assessment-Past, present, and future
    Brooks, Amy
    Candolfi, Marco
    Kimmel, Stefan
    Poulsen, Veronique
    [J]. ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2015, 34 (07) : 1454 - 1456
  • [8] Applications of mechanistic data in risk assessment: The past, present, and future
    Haber, LT
    Maier, A
    Zhao, QY
    Dollarhide, JS
    Savage, RE
    Dourson, ML
    [J]. TOXICOLOGICAL SCIENCES, 2001, 61 (01) : 32 - 39
  • [9] Risk-need assessment with juvenile offenders: Past, present and future
    Thompson, AP
    [J]. AUSTRALIAN JOURNAL OF PSYCHOLOGY, 2005, 57 : 261 - 261
  • [10] Risk assessment of drugs, biologics and therapeutic devices: present and future issues
    Strom, BL
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (08) : 653 - 662